%0 Journal Article
%A Suárez-García, Inés
%A Moreno, Cristina
%A Ruiz-Algueró, Marta
%A Pérez-Elías, María Jesús
%A Navarro, Marta
%A Díez Martínez, Marcos
%A Viciana, Pompeyo
%A Pérez-Martínez, Laura
%A Górgolas, Miguel
%A Amador, Concha
%A de Zárraga, Miguel Alberto
%A Jarrín, Inma
%A Cohort of the Spanish HIV/AIDS Research Network (CoRIS)
%T Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
%D 2020
%U http://hdl.handle.net/10668/15964
%X The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL)  We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL  EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.
%K Cohort studies
%K Darunavir
%K HIV infection
%K Highly active antiretroviral therapy
%~